Skip to main content

CORRECTION article

Front. Immunol., 01 July 2024
Sec. Vaccines and Molecular Therapeutics

Corrigendum: Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

  • 1Kidney Transplant Unit, Nephrology Department. Montpellier University Hospital, Montpellier, France
  • 2Kidney transplant Unit. Nephrology Department. Vall d’Hebron Hospital Universitari, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • 3Laboratoryof Nephrology and Transplantation. Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
  • 4Kidney transplant Unit, Nephrology Department. Grenoble University Hospital, Grenoble, France
  • 5Centro Nacional de Gripe de Valladolid, Universidad de Valladolid, Valladolid, Spain
  • 6Centro Nacional de Gripe, Valladolid Universidad de Valladolid, Valladolid, Spain
  • 7Department of Microbiology and Parasitology, Rio Hortega University Hospital, University of Valladolid, Valladolid, Spain
  • 8Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Spain
  • 9Immunology Department, Bellvitge University Hospital, Barcelona, Spain
  • 10Department of Preventive Medicine, Bellvitge University Hospital, Barcelona, Spain

A Corrigendum on
Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

by Pernin V, Meneghini M, Torija A, Jouve T, Del Bello A, Sanz-Muñoz I, Eiros J M, Donadeu L, Polo C, Morandeira F, Navarro S, Masuet C, Favà A, LeQuintrec M, Kamar N, Crespo E and Bestard O (2022). Front. Immunol. 13:918887. doi: 10.3389/fimmu.2022.918887

In the published article, there was an error in Table 1 as published. While it stated that 3 (33%) patients received the “Chiromas” vaccine, the correct information is that 3 (33%) patients in the belatacept group received the “Vaxigrip” vaccine. The corrected Table 1 and its caption appear below.

Table 1
www.frontiersin.org

Table 1 Main characteristics of the study population.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: kidney transplantation, co-stimulation blockade, memory B cells, influenza vaccination, calcineurin inhibitors, T follicular helper (Tfh) cell

Citation: Pernin V, Meneghini M, Torija A, Jouve T, Del Bello A, Sanz-Muñoz I, Eiros JM, Donadeu L, Polo C, Morandeira F, Navarro S, Masuet C, Favà A, LeQuintrec M, Kamar N, Crespo E and Bestard O (2024) Corrigendum: Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept. Front. Immunol. 15:1447503. doi: 10.3389/fimmu.2024.1447503

Received: 11 June 2024; Accepted: 19 June 2024;
Published: 01 July 2024.

Edited and Reviewed by:

Adam Wheatley, The University of Melbourne, Australia

Copyright © 2024 Pernin, Meneghini, Torija, Jouve, Del Bello, Sanz-Muñoz, Eiros, Donadeu, Polo, Morandeira, Navarro, Masuet, Favà, LeQuintrec, Kamar, Crespo and Bestard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Oriol Bestard, oriol.bestard@vallhebron.cat

These authors have contributed equally to this work and share first authorship

‡These authors share senior authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.